Loading...
•
Dec 31, 2019
Castle Biosciences Q4 2019 Earnings Report
Announced fourth quarter and full-year 2019 results.
Key Takeaways
Castle Biosciences reported strong Q4 2019 results with revenue of $17.6 million, a significant increase compared to Q4 2018. The company also saw growth in DecisionDx-Melanoma and DecisionDx-UM test reports delivered.
Revenue was $17.6 million in the fourth quarter of 2019, compared to $11.4 million in the fourth quarter of 2018.
Adjusted revenue was $17.6 million in the fourth quarter of 2019, compared to $6.2 million in the fourth quarter of 2018.
Delivered 4,480 DecisionDx-Melanoma test reports in the fourth quarter of 2019, which represents 37% growth compared to the 3,270 reports delivered during the fourth quarter of 2018.
Gross margin in the fourth quarter of 2019 was 89%.
Forward Guidance
Castle Biosciences anticipates generating $61-64 million in revenue in 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...